S&P TSX Capped Composite...

US Dollar vs CAD

Level up your trading with our powerful tools and real-time insights all in one place.

Get Started

AVIR Atea Pharmaceuticals Inc

3.45

0.10 (2.99%)

Jan 02 2025 - Closed

Delayed by 15 minutes

Form 144 - Report of proposed sale of securities

="/Images/box-checked.jpg" alt="Checkbox checked">

144: Remarks and Signature

Remarks

Date of Notice

09/17/2024

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

03/04/2024

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

/s/ UBS Financial Services Inc, as attorney-in-fact for JPM Partners LLC

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

Atea Pharmaceuticals (NASDAQ:AVIR)
Historical Stock Chart
From Dec 2024 to Jan 2025

Click Here for more Atea Pharmaceuticals Charts.

Atea Pharmaceuticals (NASDAQ:AVIR)
Historical Stock Chart
From Jan 2024 to Jan 2025

Click Here for more Atea Pharmaceuticals Charts.

Atea Pharmaceuticals Inc News

Atea Pharmaceuticals Retains Financial Advisor to Explore Strategic Partnerships
Monday 16 December 2024 (3 weeks ago) • GlobeNewswire Inc.

Atea Pharmaceuticals Announces Positive Results from Phase 2 Study of Bemnifosbuvir and Ruzasvir Regimen for Treatment of Hepatitis C Virus (HCV)
Wednesday 4 December 2024 (4 weeks ago) • GlobeNewswire Inc.

Atea Pharmaceuticals to Present and Provide a Business Update at the 7th Annual Evercore HealthCONx Conference
Tuesday 26 November 2024 (1 month ago) • GlobeNewswire Inc.

Form EFFECT - Notice of Effectiveness
Tuesday 19 November 2024 (1 month ago) • Edgar (US Regulatory)

Atea Pharmaceuticals Presents Multiple New Datasets Supporting the Combination of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at AASLD’s The Liver Meeting 2024
Friday 15 November 2024 (2 months ago) • GlobeNewswire Inc.

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Thursday 7 November 2024 (2 months ago) • Edgar (US Regulatory)

Form 8-K - Current report
Thursday 7 November 2024 (2 months ago) • Edgar (US Regulatory)

Atea Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update
Thursday 7 November 2024 (2 months ago) • GlobeNewswire Inc.

Atea Pharmaceuticals to Host Third Quarter 2024 Financial Results Conference Call on November 7, 2024
Thursday 31 October 2024 (2 months ago) • GlobeNewswire Inc.

Atea Pharmaceuticals to Present New Data Supporting the Combination of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at AASLD’s The Liver Meeting 2024
Wednesday 30 October 2024 (2 months ago) • GlobeNewswire Inc.

Form 144 - Report of proposed sale of securities
Thursday 19 September 2024 (3 months ago) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Wednesday 18 September 2024 (3 months ago) • Edgar (US Regulatory)

More Atea Pharmaceuticals Inc News Articles

Accredited Solutions (PK)

Quantum eMotion (QB)

TPT Global Tech (CE)

Fannie Mae (QB)

Valiant Eagle (PK)

Apple Rush (PK)

RespireRx Pharmaceuticals (CE)

Anavex Life Sciences

Kraig Biocraft Laborator... (QB)

Moon Equity (PK)

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions